Journal of Medical Economics

Article	Citations
Economic evaluation of supplemental breast cancer screening modalities to mammography or digital breast tomosynthesis in women with heterogeneously and extremely dense breasts and average or intermedi	140
Prolonged progression-free survival with zanubrutinib in relapsed/refractory CLL: an indirect treatment comparison versus other BTK inhibitors using multilevel network meta-regression	51
Levalbuterol vs. albuterol for hospitalized patients with COPD in China: cost-utility and budget impact analysis	50
The economic burden of systemic lupus erythematosus in Taiwan	48
Trends in industry-sponsored clinical trial activity since passage of the Inflation Reduction Act	43
The economic impact of tobacco smoking and secondhand smoke exposure in Jordan: estimating the direct and indirect costs	42
Healthcare resource utilization patterns among patients with Parkinson’s disease psychosis and dementia: analysis of US Medicare beneficiaries treated with pimavanserin versus other-atypical antipsych	41
Hexaminolevulinate-enhanced photodynamic diagnosis in the management of non-muscle-invasive bladder cancer (NMIBC): the influence of differing European health care payment systems on the potential fin	37
Economic value of intra-articular knee OA therapies: a U.S. perspective	35
Budget impact analysis of cenobamate, a novel adjunctive therapy for the treatment of drug resistant focal onset seizures, from the Belgian healthcare payer perspective	30
Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2– advanced breast cancer: a Medicare perspective	28
Calculating cost per event avoided using a composite number needed to treat	27
Number needed to treat (NNT) with pembrolizumab as an adjuvant therapy in resected patients with high-risk stage II (IIB and IIC) melanoma and its application to cost of preventing an event (COPE) in	27
Analysis of healthcare resource utilization before and after initiation of maribavir for cytomegalovirus treatment	26
A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphom	25
The economic impact of suboptimal treatment and treatment switch among patients with Crohn’s disease treated with a first-line biologic – A US retrospective claims database study	25
Health care resource utilization in the management of patients with Arginase 1 Deficiency in the US: a retrospective, observational, claims database study	24
Projected clinical and economic benefits of improved patent foramen ovale testing among cryptogenic stroke patients in the United States	24
Micro-costing of genetic diagnostics in acute leukemia in Sweden: from standard-of-care to whole-genome sequencing	23
Economic burden of respiratory syncytial virus infection in adults: a systematic literature review	23
Cost-effectiveness analysis of atezolizumab and bevacizumab as first-line systemic therapy in unresectable hepatocellular carcinoma in Malaysia	22
Correction	22
Reforming the delivery of smoking cessation: a distributional cost-effectiveness analysis of providing smoking cessation as part of targeted lung cancer screening	22
Challenges in health economics research: insights from real-world examples	20
Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm	20

Reply to letter by Hadigal et al. regarding the cost-effectiveness of high dose quadrivalent vaccine in three European countries	20
Initiating immunoglobulin replacement therapy helps reduce severe infections and shifts healthcare resource utilization to outpatient services among US patients with inborn errors of immunity	19
The impact of diagnosing provider type on longitudinal care for patients with newly diagnosed Huntington’s disease	19
Projected hospitalization cost impact of the selective cytopheretic device in pediatric acute kidney injury	19
Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries	18
Transforming PAH care in Italy: a clinical and economic evaluation of sotatercept add-on therapy	18
Utilities associated with stoma-related complications: peristomal skin complications and leakages	18
Effects of liposomal bupivacaine (LB) and provider experience with LB on service utilization, clinical outcomes, and Medicare expenditures among fee-for-service (FFS) beneficiaries	17
Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective	17
Economic review of point-of-care EEG	17
Cost-efficiency modeling of conversion to biosimilar rituximab-based R-CHOP in diffuse large B-cell lymphoma in medicare	17
Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experiment	16
Estimation of the utilities of attributes of intravenous iron infusion treatment for patients with iron-deficiency anemia: a conjoint analysis in Japan	16
Cost-effectiveness analysis of universal hypothyroidism screening in the general population aged 30–65 years in Spain	16
Societal burden of the US opioid epidemic over the next 15 years and the potential impact of effective non-opioid treatments for pain	16
Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer	16
Healthcare costs among hemophilia A patients in the United States treated with rurioctocog alfa pegol (FVIII-PEG) or antihemophilic factor (recombinant), FC fusion protein (rFVIIIFc) using real-world	16
Effectiveness of the etonogestrel implant: an economic model of immediate postpartum use on pregnancy outcomes	16
Economic and clinical value of hydrolyzed collagen in the management of spine surgery wounds: a cost-effectiveness analysis	15
Inflation-adjusted analysis of ICER’s Unsupported Price Increase reports: contextualizing drug spending changes	15
The budget impact of utilizing the Oncotype DX Breast Recurrence Score test from a US healthcare payer perspective	15
Clinical and healthcare burden of myotonic dystrophy type 1 (DM1) in the United States: a claims-based study	15
The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland	15
Cost-effectiveness of CMR over MPS-SPECT: a systematic review of recent trends for diagnosing CAD	15
Healthcare resource utilization and costs associated with first versus subsequent use of cariprazine for bipolar I disorder	14
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in F	14
Real-time continuous glucose monitoring vs. self-monitoring of blood glucose: cost-utility in South Korean type 2 diabetes patients on intensive insulin	14
Cost-effectiveness of intravenous resuscitation fluids in sepsis patients: a patient-level data analysis in Jordan	14
Cost-effectiveness of volume computed tomography in lung cancer screening: a cohort simulation based on Nelson study outcomes	14
The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data	13
Cost analysis of disease including treatment with dalbavancin in a Spanish hospital: ECODAL ANALYSIS	13
Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission – a UK case study	13
A discrete-choice experiment to elicit the treatment preferences of patients with hidradenitis suppurativa in the United States	13
Economic burden of respiratory syncytial virus in adults in Germany – a health claims analysis between 2015 and 2018	13
The economic value of insulin glargine 300 U/mL (Gla-300) in people ≥18 years of age with type 2 diabetes mellitus: a value-based economic model from a U.S. payer perspective	13
Value of germline BRCA testing in patients with breast cancer: critical review of cost-effectiveness analyses using published value frameworks	13
Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective	13
The indirect costs of vaccine-preventable cancer mortality in the Middle East and North Africa (MENA)	13
Budget impact analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands	12
Evaluating cost-effectiveness of PFO management strategies: closure with Cardioform vs. Amplatzer, and treatment with medical therapy alone, for secondary stroke prevention	12
Cost-effectiveness analysis of intradiscal condoliase injection vs. surgical or conservative treatment for lumbar disc herniation	12
Cost-effectiveness analysis of seasonal influenza vaccination compared to no vaccination in the United Arab Emirates and Iraq	12
Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan	12
Gastric cancer in Spain: evaluating productivity loss and economic impact	12
Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China	12
A review of the cost-effectiveness of genetic testing for germline variants in familial cancer	12
Cost-minimisation analysis of anti-VEGF therapies in neovascular age-related macular degeneration and diabetic macular oedema in Switzerland	12
An evaluation of the best practices and barriers for the Nagasaki acute myocardial infarction secondary prevention clinical pathway	11
Correction	11
Decision model to evaluate the cost of clinical events associated with switching from apixaban to rivaroxaban among patients with non-valvular atrial fibrillation in the United States and Germany	11

Economic and clinical burden of managing transfusion-dependent β-thalassemia in the United States	11
A cost-consequence analysis comparing three cardiac ablation strategies for the treatment of paroxysmal atrial fibrillation	11
Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain	11
Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada	11
Population health outcomes of blood-based screening for colorectal cancer in comparison to current screening modalities: insights from a discrete-event simulation model incorporating longitudinal adhe	11
Publisher’s note	11
Economic impact associated with dronedarone use in patients with atrial fibrillation	11
Cost per remission for mirikizumab versus ustekinumab for moderately to severely active ulcerative colitis treatment from the United States commercial payer perspective	11
Economic burden of COVID-19 for employers and employees in the United States	10
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1	10
Correction	10
Use of external data to inform overall survival extrapolation in NICE technology appraisals for oncology drugs	10
Cost comparison of osimertinib plus platinum-pemetrexed versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor	10
Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis	10
Cost-effectiveness analysis of sodium zirconium cyclosilicate for hyperkalemia among patients with chronic kidney disease or heart failure in Kuwait	10
Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain	10
Correction	10
Benefits of MR-proADM-guided decision-making in the emergency department: clinical and economic evaluation in Italy, Germany, Spain, and the UK	10
Economic impact analysis of a minimally invasive temperature-controlled radiofrequency device versus nasal surgery for the treatment of nasal airway obstruction in the United States	10
Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Colombia	10
Optimizing the delivery of genetic and advanced diagnostic testing in the province of Ontario: challenges and implications for laboratory technology assessment and management in decentralized healthca	10
Validation of overall survival extrapolations made by TLV in the assessment of cost-effectiveness of oncology drugs in Sweden – A pilot study comparing extrapolated and observed life-years gained	9
Increased use of 6-monthly gonadotropin-releasing hormone agonist therapy for prostate cancer: a capacity and cost-minimization analysis for England	9
Cost drivers and delays in recovery following rotator cuff repair: insights from a national claims database	9
Association between timing of adjunctive brexpiprazole initiation and healthcare resource use and costs in major depressive disorder	9
Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison	9
Corneal cross-linking for keratoconus: a global economic and clinical perspective	9
Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison	9
Cost-effectiveness of targeted screening for non-valvular atrial fibrillation in the United Kingdom in older patients using digital approaches	9
Cost effectiveness of implantable cardioverter defibrillators for 1.5 primary prevention of sudden cardiac arrest in China: an analysis from the Improve SCA study	9
A prospective cohort study estimating total pre-surgical healthcare costs before and two-year total societal costs after resective brain surgery, and quality of life of patients with drug-resistant ep	9
Cost-effectiveness analysis of rapid antibiotic susceptibility testing as a point of care for patients with uncomplicated urinary tract infection in Japan	9
Addendum	9
Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants	8
The economic burden of recurrence in elderly patients with completely resected, stage IIB/IIC or III melanoma: an analysis of the Surveillance, Epidemiology, and End Results-Medicare linked database	8
A value assessment of patient-level outcomes and productivity loss for intravenous and subcutaneous lecanemab for patients with early Alzheimer’s disease	8
Post-approval indications and clinical trials for cardiovascular drugs: some implications of the US Inflation Reduction Act	8
Identification of undiagnosed atrial fibrillation using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI) in primary care: cost-effectiveness of a screening strategy evalu	8
Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system persp	8
The epidemiology and healthcare costs of community-acquired pneumonia in Ontario, Canada: a population-based cohort study	8
Promoting equality in utilization of basic public health services in China: the role of the family doctor contract service	8
Cost implications of introducing the BIOFIRE FILMARRAY meningitis/encephalitis panel vs. real-time PCR in adult and pediatric populations in the UK	8
Real-world perioperative treatment patterns and economic burden of recurrence in early-stage HER2-negative breast cancer: a SEER-Medicare study	8
Racial variation in healthcare resource utilization and expenditures in knee/hip osteoarthritis patients: a retrospective analysis of a Medicaid population	8
Cost-effectiveness of vasopressin in the treatment of septic shock: insights from a European societal perspective	8
Budget impact of introducing an omalizumab biosimilar in 23 European countries	8
Correction	8
Comparison of utilization and cost of healthcare services and pharmacotherapy following implantation of vagus nerve stimulation vs. responsive neurostimulation or deep b	8
Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results	8
Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States	8
Moving preinduction cervical ripening to a lower acuity inpatient setting using the synthetic hygroscopic cervical dilator: a cost-consequence analysis for the United States	8
Budget impact model of acellular tissue engineered vessel for the repair of extremity arterial trauma when autologous vein is not feasible	8
Validation of the IHE type 2 diabetes cohort model in the Japanese clinical setting	7
Foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson’s disease (aPD): demonstration of savings from a societal perspective in the UK	7
U.S. payer budget impact of using an AI-augmented cancer risk discrimination digital histopathology platform to identify high-risk of recurrence in women with early-stage invasive breast cancer	7
Impact of offering blood-based testing alongside existing modalities for colorectal cancer screening among those who previously declined screening: an economic evaluation	7
Health care resource utilization patterns among patients with Parkinson’s disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics	7
Impact of rifaximin use following an initial overt hepatic encephalopathy hospitalization on rehospitalization and costs	7
Economic impact of MAF testing for adjuvant bisphosphonate therapy in early breast cancer: a multi-regional budget impact analysis from a payer perspective	7
Cost-utility of implantable tibial neuromodulation (Revi) versus conservative therapy for urgency urinary incontinence in adults: a US payer perspective	7
Advancing towards a worldwide healthcare system in the post-COVID-19 era: benefits and barriers to international collaboration in healthcare	7
The economic burden of Ebola virus disease: a review and recommendations for analysis	7
Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid or	7
Cost-effectiveness analysis of artificial intelligence (AI) in earlier detection of liver lesions in cirrhotic patients at risk of hepatocellular carcinoma in Italy	7
Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States	7
Cost-effectiveness of add-on empagliflozin versus standard of care in management of CKD in Malaysia, Thailand and Vietnam – findings from a modelling study assessing an EMPA-KIDNEY eligible population	7
Quantifying treatment value under IRA: a case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measures	7
Clinical and methodological uncertainty in the economic evaluation of suzetrigine	7
Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan	7
Estimating the public health and economic impact of increased COVID-19 annual vaccination coverage in the 60 years and older population in Spain	7
Reply letter to “Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal”	7
Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait	7
Short- and long-term cost-effectiveness of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis in China	7
Cost of invasive pneumococcal disease, all-cause pneumonia, and all-cause otitis media among commercial-insured US children	6
Willingness to pay for the effect of SARS-CoV-2 antivirals in preventing COVID-19 transmission to others in the Japanese population	6
Burden and indirect cost of vaccine-preventable cancer mortality in Europe	6
Technical and regulatory challenges of digital health implementation in developing countries	6
Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma	6
Global burden of disease due to young-onset dementia and the forecast for 2050: update from global burden of disease study 2021	6
An Italian cost-utility analysis of 20-valent pneumococcal conjugate vaccine for routine vaccination in infants	6

Evaluation of the health economic impact of initial diagnostic modality selection in patients suspected of having HCC in China and the USA	6
Burden of COVID-19 during the omicron predominance in Brazil: a nationwide retrospective database study	6
The biologic paradox solved? The imminent arrival of omalizumab biosimilars in Europe	6
Comparative cost-effectiveness of ribociclib and palbociclib as first-line treatment for HR+/HER2– advanced breast cancer in postmenopausal women: analysis from a Medicare perspective	6
Value frameworks for digital health technologies: a comparative analysis	6
Economic option value associated with surgical aortic valve replacement using a novel bioprosthetic and a future transcatheter aortic valve-in-valve procedure	6
RETRACTED ARTICLE: Foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson’s Disease (aPD): demonstration of savings from a societal perspective in the UK	6
Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US	6
Using system dynamics modeling approach to strengthen health systems to combat cancer: a systematic literature review	6
Cost-consequence analysis of three cardiac ablation technologies in paroxysmal atrial fibrillation	6
Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-cell lymphoma	6
Place of care and costs associated with acute episodes and remission in bipolar I disorder	6
Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study	6
Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021	6
Autologous skin cell suspension plus phototherapy in stable vitiligo: findings from a US economic model	6
Comparison of statistical methods for extrapolating survival in previously untreated diffuse large B-cell lymphoma: results based on the POLARIX study	6
Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States	6
Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galca	6
Measurement and valuation of the attributes of innovation of healthcare technologies: a systematic review	6
Estimating the societal economic burden of food allergy in the United States	6
Cost-efficiency and expanded access modeling of conversion to biosimilar bevacizumab in metastatic colorectal and non-squamous non-small cell lung cancer in Medicare	6
Real-world healthcare resource utilization and clinical outcomes among patients with relapsed/refractory multiple myeloma receiving ciltacabtagene autoleucel after four or more prior lines of therapy	6
Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK	6
The budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States	6
Cost-effectiveness of Left Atrial Appendage Closure with WATCHMAN device for non-valvular atrial fibrillation patients in Japan. Are the policy implications big in Japan?	6
Impact of choice of inhalers for asthma care on global carbon footprint and societal costs: a long-term economic evaluation	6
Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China	5
Longitudinal analyses of healthcare resource utilization and costs among patients with obstructive hypertrophic cardiomyopathy	5
Assessing the fiscal consequences of novel and existing treatments for triple negative breast cancer in Switzerland by applying a government perspective framework	5
Health-economic impact of implementing continuous vital sign monitoring in post-surgical patients in five European countries	5
The burden of venous thromboembolism in ten countries: a cost-of-illness Markov model on surgical and ICU patients	5
A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands	5
Prostate cancer progression: a scoping review, pharmacoeconomic assessment, and evaluation of quality of life	5
Economic burden of growth hormone deficiency among adults who are at risk for and who have confirmed growth hormone deficiency using US real-world data	5
Cardio-renal-metabolic modeling in Asia-Pacific: projections of clinical and economic burden and empagliflozin’s impact on burden reduction	5
A cost-consequences and budget impact analysis of blue light-guided cystoscopy with Hexvix in patients diagnosed with non-muscle-invasive bladder cancer in France	5
Cost-effectiveness of finerenone therapy for patients with chronic kidney disease and type 2 diabetes in England & Wales: results of the FINE-CKD model	5
Correction	5
Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials	5
Budget impact of prophylactic treatment of rVIII-SingleChain in moderate and severe hemophilia A in Italy	5
Cost-effectiveness analysis of HLA-B*13:01 screening for the prevention of co-trimoxazole-induced severe cutaneous adverse reactions among HIV-infected patients in Thailand	5
Microsimulation model of the cost-effectiveness of anifrolumab compared to belimumab in the United Arab Emirates	5
Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States	5
Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States	5
National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States	5
Time to access matters: patient gains from faster CAR T-cell reimbursement in Europe	5
A systematic review of health state utility values for influenza and influenza-like illness	5
A system dynamics modelling protocol to evaluate the impact of a health financing mechanism for breast cancer pharmacotherapies in Malaysia	5
Health state utilities associated with obstructive sleep apnea: preferences of patients with OSA and obesity in the UK and the US	5
Toward an ethical future for orphan drugs: balancing access, affordability, and innovation	5
The cost-effectiveness of subcutaneous semaglutide 2.4 mg in the management of people living with obesity and prediabetes in England	5
Cost-effectiveness of left atrial appendage closure with Watchman for non-valvular atrial fibrillation patients in Japan	5
The cost-effectiveness of abobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) for managing spasticity of the upper and lower limbs, and cervical dystonia	5
Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer	5
Cost-effectiveness analysis of bispecific antibody faricimab for treatment of neovascular age-related macular degeneration and diabetic macular edema in Japan	5
Budget impact analysis of belumosudil for chronic graft-versus-host disease treatment in the United States	5
Delta price cost-effectiveness analysis of PCV21 vs PCV20 use in adults aged ≥65 years in Switzerland	5
Cost-effectiveness and public health impact of using high dose influenza vaccine in the Japanese older adults	5
Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis	5
Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on	5
Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin immunotherapy	5
Nirmatrelvir/ritonavir treatment for COVID-19: an economic value systematic literature review	5
An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug resistant epilepsy in the United States	5
The cost-effectiveness of a nursing home-based transitional care unit for increasing the potential for independent living in the community among hospitalized older adults	5
Cost-effectiveness of TOMAC therapy for medication-refractory restless legs syndrome: an updated analysis based on Extension study data	5
The role of sodium zirconium cyclosilicate drug utilization in managing hyperkalemia: impact on healthcare resource utilization and on maintenance of renin-angiotensin-aldosterone system inhibitor the	5
Evaluating the broad societal value of pembrolizumab in women’s cancer in Brazil	5
The indirect costs and burden of vaccine-preventable cancers premature mortality in Asia-Pacific countries	5